Literature DB >> 29310474

Low prevalence of hepatitis E in Iceland: a seroepidemiological study.

Arthur Löve1,2, Thora B Björnsdottir2, Sigurdur Olafsson3, Einar S Björnsson1,3.   

Abstract

OBJECTIVE: Hepatitis E virus (HEV) infection has been reported to be more prevalent in the developed countries than previously thought. HEV infection is an important differential diagnosis in patients with drug-induced liver injury (DILI). The prevalence of hepatitis E was investigated in the general population of Iceland, among pig farmers and patients with DILI.
MATERIALS AND METHODS: Serum samples were tested for hepatitis E IgG, with two commercial ELISA tests: Diagnostic Bioprobes Srl. (Dia Pro) and the Wantai HEV IgG and subjects repeatedly reactive were tested with an immunoblot assay (RecomLINE). Three groups were tested: (1) healthy volunteers (HV), (2) pig farm workers (PFWs) and (3) patients participating in a nationwide prospective study on DILI.
RESULTS: Overall 291 individuals were tested, HV (n = 195), PFW (n = 21) and DILI (n = 75). Only 6/291 (2.1%) tested positive for IgG antibodies to HEV in all three tests. Three HV were HEV IgG antibody positive and three in the DILI group. One PFW tested positive in the Dia Pro and Wantai tests but not in the immunoblot assay. All but one of the positive individuals in all three tests was either of foreign national origin or had spent extended period of time outside of Iceland.
CONCLUSIONS: The seroprevalence of hepatitis E appears to be lower in Iceland than majority of recent studies in other western countries have demonstrated. This may be due to relative isolation and severe restriction on import of livestock from other countries.

Entities:  

Keywords:  Hepatitis E; Iceland; seroepidemiology

Mesh:

Substances:

Year:  2018        PMID: 29310474     DOI: 10.1080/00365521.2017.1420218

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  4 in total

1.  Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network.

Authors:  Helgi K Björnsson; Einar S Björnsson; Bharathi Avula; Ikhlas A Khan; Jon G Jonasson; Marwan Ghabril; Paul H Hayashi; Victor Navarro
Journal:  Liver Int       Date:  2020-02-11       Impact factor: 5.828

2.  Incidence of Hepatitis E Infection in American Patients With Suspected Drug-Induced Liver Injury Is Low and Declining: The DILIN Prospective Study.

Authors:  Robert John Fontana; Ronald E Engle; Paul H Hayashi; Jiezhun Gu; David E Kleiner; Hahn Nguyen; Huiman Barnhart; Jay H Hoofnagle; Patrizia Farci
Journal:  Am J Gastroenterol       Date:  2022-06-10       Impact factor: 12.045

3.  Systematic review and meta-analysis of the seroprevalence of hepatitis E virus in the general population across non-endemic countries.

Authors:  Barbara Wilhelm; Lisa Waddell; Judy Greig; Ian Young
Journal:  PLoS One       Date:  2019-06-07       Impact factor: 3.240

4.  Seroprevalence of hepatitis E virus in dromedary camels, Bedouins, Muslim Arabs and Jews in Israel, 2009-2017.

Authors:  R Bassal; M Wax; R Shirazi; T Shohat; D Cohen; D David; S Abu-Mouch; Y Abu-Ghanem; E Mendelson; Z Ben-Ari; O Mor
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.